Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Vericiguat (Verquvo) is indicated to reduce the risk of cardiovascular death and heart failure hospitalization in adults with symptomatic chronic heart failure and ejection fraction below 45%.
• Seven studies provided a comprehensive comparison of Vericiguat's safety and effectiveness against other heart failure management options.
• Mixed results were observed in studies comparing Vericiguat to placebo regarding its ability to reduce cardiovascular death or heart failure hospitalization. However, in comparison with sacubitril/valsartan and sodium-glucose cotransporter 2 inhibitors, it was demonstrated that all these options could potentially decrease hospitalizations or deaths from cardiovascular causes in patients with reduced ejection fraction.
• The safety profile of Vericiguat varies; common adverse effects include hypotension, syncope, and anemia. Similar rates for safety and efficacy endpoints were observed when compared with another sGC stimulator (riociguat), suggesting consistency within its class.
• Subgroup analysis revealed that Vericiguat reduces risks associated with cardiovascular death and heart failure hospitalization in patients suffering from Heart Failure with Reduced Ejection Fraction (HFrEF), but does not show a therapeutic effect on Heart Failure with Preserved Ejection Fraction (HFpEF).
• The effectiveness of Vericiguat across a broad spectrum of NT-proBNP levels up to 8000 pg/ml indicates its potential usefulness across various degrees of severity related to heart failures.